Q1'22 Redsense Medical rapporterade nettoomsättning på 3,1 mkr i Q1'22, upp från 0,7 mkr i Q1'21, mo...
Egen produktion fortsätter att glänsa Arise nettoomsättning uppgick till 88 (47) mkr och EBIT till 4...
Q1 marked a return to normal gross margins NWT ramp-up lagging expectations, sales down 7-3% 15-10x ...
Redeye expects another stable quarter from Starbreeze.
Redeye raises its Base Case and forecasts following a Q1 report beating our estimates significantly.
Redeye raises its forecasts in Addnode following a solid Q1, with solid margins in all three Divisio...
Redeye will likely retain its positive view on Transtema following a Q1 report with comparable figur...
Redeye is positive about Catella's acquisition of WPP.
Redeye updates estimates and valuation post Stillfront’s Q1-results which came in above our expectat...
Redeye is encouraged by yet another record quarter by BONESUPPORT, but we have made some considerabl...
Cibus posted Q1 net operating income of EUR 21.8m, up 20% y/y on the back of acquisitions and 2% abo...
Redeye saw sales in line with our expectations for the quarter.
Q1 sales +27% vs ABGSC, a growth of 54% y-o-y Positive EBITDA at SEK 1.
Redeye comments on G5’s Q1-results which adjusted for extraordinary costs related to the war in Ukra...
Redeye finds that Westpay’s report was slightly better than expected in terms of revenue and margins...
Company activities Eastnine aims to run a climate-neutral organisation and is targeting net zero ca...
We revise down our comparable EBITDA estimates by 8% for 2022 and 4% for 2023, reflecting the lowere...
Ferronordic's operations have been severely hit by the sanctions against Russia, as at least two of ...
Redeye initiates coverage of SenzaGen, a Swedish commercial-stage MedTech company offering high-perf...
Redeye initiates coverage of ISR Immune System Regulation Holding AB, a Swedish biotech company deve...
